Recombinant virus, composition comprising the same, and uses thereof
Immunogenic compositions comprising hemagglutinin (HA) variants and/or neuraminidase (NA) variants, which may be contained in an influenza A virus, and uses thereof for eliciting immune responses against influenza A virus.
1. A recombinant Influenza A virus (IAV), comprising:
a mutant neuraminidase (NA), which, as compared with its wild-type counterpart, consists of the amino acid sequence of SEQ ID NO: 11, 12 or 13; wherein the mutant NA is defective in neuraminidase activity.
2. An immunogenic composition, comprising (i) a recombinant Influenza A virus (IAV) of claim 1 ; and (ii) a pharmaceutically acceptable carrier.
3. The immunogenic composition of claim 2 , wherein the pharmaceutically acceptable carrier is an adjuvant.
4. A method for inducing immune responses against influenza A virus in a subject, the method comprising administering to a subject in need thereof an effective amount of the immunogenic composition of claim 2 .
5. The method of claim 4 , wherein the subject is a human subject.
6. The method of claim 5 , wherein the human subject is infected, suspected of being infected, or at risk for infection by an influenza A virus.
7. The method of claim 6 , wherein the influenza A virus is an H1N1 or H5N1 influenza A virus.
8. The method of claim 4 , wherein the immunogenic composition is administered to the subject via a route selected from the group consisting of oral administration, enteral administration, nasal administration, topical administration, and transmucosal administration.
9. The method of claim 4 , wherein the immunogenic composition is administered to the subject parenterally.